📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Entrada Therapeutics

1.1 - Company Overview

Entrada Therapeutics Logo

Entrada Therapeutics

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of a proprietary EEV platform to target and engage typically inaccessible intracellular disease targets, with therapeutic programs using EEV-oligonucleotides. Pipeline includes Duchenne muscular dystrophy candidates ENTR-601-44, ENTR-601-45 and ENTR-601-50 for exon skipping to restore dystrophin, and a myotonic dystrophy type 1 program to restore MBNL protein activity in collaboration with Vertex.

Products and services

  • Duchenne Muscular Dystrophy Program: Oligonucleotide-based program developing EEV-Oligonucleotides to address genetic causes and restore functional dystrophin in muscle cells using targeted intracellular engagement
  • EEV™ Platform: Proprietary platform that targets and engages disease-causing targets within cells typically inaccessible, supporting therapeutic applications across diverse areas with intracellular target access
  • Myotonic Dystrophy Type 1 Program: MBNL-targeted program architected with EEV-Oligonucleotides to restore MBNL protein activity in myotonic dystrophy type 1, advanced via collaboration with Vertex.

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Entrada Therapeutics

GeneTx Biotherapeutics Logo

GeneTx Biotherapeutics

HQ: United States Website
  • Description: Provider of biotechnology therapeutics focused on Angelman syndrome, offering investigational gene and antisense therapies. Pipeline includes GTX-102 for Angelman syndrome (delivering a functional UBE3A gene to the brain), UX055 for CDKL5 Deficiency Disorder, and UX111 for Sanfilippo syndrome type A, with a commitment to clinical trial transparency including trial registration, results publication, and data sharing.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full GeneTx Biotherapeutics company profile →
Harmony Biosciences Logo

Harmony Biosciences

HQ: United States Website
  • Description: Provider of novel therapies for rare neurological disorders, including U.S. commercialization of pitolisant, a histamine-3 receptor antagonist/inverse agonist approved for narcolepsy; developing HBS-102, a melanin-concentrating hormone receptor 1 antagonist; and evaluating pitolisant for idiopathic hypersomnia, Prader-Willi syndrome, and myotonic dystrophy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Harmony Biosciences company profile →
Amryt Pharma Logo

Amryt Pharma

HQ: Ireland Website
  • Description: Provider of specialty pharmaceuticals for rare and orphan diseases: Myalept/Myalepta (metreleptin) for leptin deficiency complications in generalized or partial lipodystrophy; Mycapssa (octreotide capsules) for long-term maintenance therapy in acromegaly; Juxtapid/Lojuxta (lomitapide) for adults with HoFH; Filsuvez (Oleogel-S10) for partial-thickness wounds in junctional and dystrophic EB; and AP103, a pre-clinical gene therapy for DEB.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Amryt Pharma company profile →
Castle Creek Biosciences Logo

Castle Creek Biosciences

HQ: United States Website
  • Description: Provider of personalized gene therapies for rare skin and connective tissue disorders, including D-Fi (dabocemagene autoficel) for dystrophic epidermolysis bullosa using autologous genetically modified fibroblasts to express type VII collagen; an autologous fibroblast technology platform; in-house cGMP commercial-scale manufacturing; and an expanded access policy for investigational products.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Castle Creek Biosciences company profile →
Aspreva Pharmaceuticals Logo

Aspreva Pharmaceuticals

HQ: Canada Website
  • Description: Provider of pharmaceutical solutions focused on identifying, developing and commercializing new indications for approved drugs and drug candidates for underserved patient populations. Headquartered in Victoria, British Columbia, the company uses a collaboration strategy termed 'indication partnering'.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Aspreva Pharmaceuticals company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Entrada Therapeutics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Entrada Therapeutics

2.2 - Growth funds investing in similar companies to Entrada Therapeutics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Entrada Therapeutics

4.2 - Public trading comparable groups for Entrada Therapeutics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Entrada Therapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Entrada Therapeutics

What does Entrada Therapeutics do?

Entrada Therapeutics is a provider of a proprietary EEV platform to target and engage typically inaccessible intracellular disease targets, with therapeutic programs using EEV-oligonucleotides. Pipeline includes Duchenne muscular dystrophy candidates ENTR-601-44, ENTR-601-45 and ENTR-601-50 for exon skipping to restore dystrophin, and a myotonic dystrophy type 1 program to restore MBNL protein activity in collaboration with Vertex.

Who are Entrada Therapeutics's competitors?

Entrada Therapeutics's competitors and similar companies include GeneTx Biotherapeutics, Harmony Biosciences, Amryt Pharma, Castle Creek Biosciences, and Aspreva Pharmaceuticals.

Where is Entrada Therapeutics headquartered?

Entrada Therapeutics is headquartered in United States.

How many employees does Entrada Therapeutics have?

Entrada Therapeutics has 1,000 employees 🔒.

When was Entrada Therapeutics founded?

Entrada Therapeutics was founded in 2010 🔒.

What sector and industry vertical is Entrada Therapeutics in?

Entrada Therapeutics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Entrada Therapeutics

Who are the top strategic acquirers in Entrada Therapeutics's sector and industry

Top strategic M&A buyers and acquirers in Entrada Therapeutics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Entrada Therapeutics?

Top strategic M&A buyers groups and sectors for Entrada Therapeutics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Entrada Therapeutics's sector and industry vertical

Which are the top PE firms investing in Entrada Therapeutics's sector and industry vertical?

Top PE firms investing in Entrada Therapeutics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Entrada Therapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Entrada Therapeutics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Entrada Therapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Entrada Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Entrada Therapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Entrada Therapeutics?

The key public trading comparables and valuation benchmarks for Entrada Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Entrada Therapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Entrada Therapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Entrada Therapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Entrada Therapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Entrada Therapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in Entrada Therapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Entrada Therapeutics